Live and let die: A new suicide gene therapy moves to the clinic

Molecular Therapy

Volumn 20, Issue 1, 2012, Pages 11-13

  Morgan, Richard A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AP 1903; CASPASE 9; GANCICLOVIR; MOLECULAR THERAPY AGENT; SITIMAGENE CERADENOVEC; UNCLASSIFIED DRUG;

APOPTOSIS; DNA FRAGMENTATION; DRUG RESPONSE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; LEUKEMIA; LONG TERMINAL REPEAT; NOTE; OVARY CANCER; STEM CELL TRANSPLANTATION; SUICIDE GENE THERAPY;

EID: 84856964331     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.273     Document Type: Note

References (11)

1. Di Stasi, A, Tey, S-K, Dotti, G, Fujita, Y, Kennedy-Nasser, A, Martinez, C et al. (2011). Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365: 1673-1683.
2. Moolten, FL (1986). Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 46: 5276-5281. (Pubitemid 16008301)
3. Altaner, C (2008). Prodrug cancer gene therapy. Cancer Lett. 270: 191-201.
4. Bonini, C, Ferrari G, Verzeletti, S, Servida, P, Zappone, E, Ruggieri, L et al. (1997). HSV-TK gene transfer into donor lymphocytes for control of allogeneic graftversus-leukemia. Science 276: 1719-1724. (Pubitemid 27421983)
5. Lupo-Stanghellini, MT, Provasi, E, Bondanza, A, Ciceri, F, Bordignon, C and Bonini, C (2010). Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation. Hum Gene Ther 21: 241-250.
6. Tey, SK, Dotti, G, Rooney, CM, Heslop, HE and Brenner, MK (2007). Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 13: 913-924. (Pubitemid 47055386)
7. Burns, WR, Zheng, Z, Rosenberg, SA and Morgan, RA (2009). Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation. Blood 114: 2888-2899.
8. Hacein-Bey-Abina, S, von Kalle, C, Schmidt, M, Le Deist, F, Wulffraat, N, McIntyre, E et al. (2003). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348: 255-256. (Pubitemid 36077924)
9. Brentjens, R, Yeh, R, Bernal, Y, Riviere, I and Sadelain, M (2010). Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 18: 666-668.
10. Morgan, RA, Yang, JC, Kitano, M, Dudley, ME, Laurencot, CM and Rosenberg, SA (2010). Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18: 843-851.
11. Kohn, DB and Candotti, F (2009). Gene therapy fulfilling its promise. N Engl J Med 360: 518-521.